* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

GPC Biotech

Eli Lilly's Dose of Disclosure (at Motley Fool)

The Fool has long stood for more disclosure and transparency for publicly traded companies. Earlier this week, pharma giant Eli Lilly (NYSE: LLY) announced that in the coming year, it would begin disclosing the fees it...

Gerhard Muller to Lead Proteros' Fragment Based Service Offering

News source: Business Wire Proteros biostructures today announced that Dr. Gerhard Muller has joined the management team to lead the company's service initiative in fragment based lead generation. Gerhard joins the Proteros...

GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2008 (Business...

Wednesday August 13, 1:35 am ET -- Company confirms that existing cash position expected to support currently planned business operations until approximately the end of 2010 MARTINSRIED, Germany & MUNICH, Germany & PRINCETON,...

Celgene Calls it Quits in GPC Satraplatin Deal

Celgene Corp. has ended its nearly three-year partnership with embattled German firm GPC Biotech AG on its prostate cancer drug satraplatin. European regulators said the drug's application, submitted in June 2007, was not...

GPC Biotech to withdraw marketing application for satraplatin

GPC Biotech has reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the marketing authorization application for satraplatin plus prednisone for the treatment of...

Analyst Actions: Amgen, American Axle

A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. But the pharma company says it strongly believes that further talks with the agency will lead to an...

GPC partners pull cancer drug application

NEW YORK - German biotechnology company GPC Biotech AG said Friday its European partner withdrew an application for the troubled cancer drug candidate satraplatin, a move made by GPC in the U.S. last year. "Although we...

GPC Biotech To Re-Schedule Annual Shareholders' Meeting (Business Wire)

MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today announced that the Company has re-scheduled its Annual Shareholders' Meeting to December 16, 2008 in Munich. The meeting was previously scheduled for August...

GPC Biotech To Re-Schedule Annual Shareholders' Meeting

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that the Company has re-scheduled its Annual Shareholders' Meeting to December 16, 2008 in Munich. The meeting was previously scheduled for August 27,...

GPC Biotech Kicks Off Phase II Trial for Prostate Cancer Drug

GPC Biotech is beginning a clinical trial testing satraplatin combined with the steroid prednisone in patients with metastatic hormone-refractory prostate cancer who have been treated with docetaxel, a chemotherapy drug....

1 2 3 4 5 next »